District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'
Allergan PLC argued that its deal with the Saint Regis Mohawk Tribe would block generic drug makers from unfairly getting a second chance to eliminate its Restasis (cyclosporine) patents. But now that a judge has ruled the patents are invalid it may regret trying to derail the inter partes review (IPR) process, since the move may end up resulting only in harm to the firm's reputation.
In an Oct. 16 order, the US District Court for the Eastern District of Texas found that four...
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Swiss major confident that new oncology drugs will fill revenue gap.
An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.
In this week's episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets.
BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.
